US Patent 9630922 3-spiro-7-hydroxamic acid tetralins as HDAC inhibitors
Patent 9630922 was granted and assigned to FORMA Therapeutics on April, 2017 by the United States Patent and Trademark Office.
Is a
Current Assignee
Date Filed
April 15, 2016
Date of Patent
April 25, 2017
Patent Applicant
Patent Application Number
15130613
Patent Jurisdiction
Patent Number
Patent Primary Examiner
Find more entities like US Patent 9630922 3-spiro-7-hydroxamic acid tetralins as HDAC inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
